|
1
|
Wang J, Song YX, Ma B, Wang JJ, Sun JX,
Chen XW, Zhao JH, Yang YC and Wang ZN: Regulatory roles of
non-coding RNAs in colorectal cancer. Int J Mol Sci.
16:19886–19919. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Konda B, Shum H and Rajdev L:
Anti-angiogenic agents in metastatic colorectal cancer. World J
Gastrointest Oncol. 7:71–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kocarnik JM, Shiovitz S and Phipps AI:
Molecular phenotypes of colorectal cancer and potential clinical
applications. Gastroenterol Rep (Oxf). 3:269–276. 2015.PubMed/NCBI
|
|
4
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang L, Bo X, Zheng Q, Xiao X, Wu L and Li
B: miR-296 inhibits proliferation and induces apoptosis by
targeting FGFR1 in human hepatocellular carcinoma. FEBS Lett.
590:4252–4262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dinami R, Buemi V, Sestito R, Zappone A,
Ciani Y, Mano M, Petti E, Sacconi A, Blandino G, Giacca M, et al:
Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent
apoptosis protection and telomere maintenance in basal-type breast
cancer cells. Oncotarget. 8:95674–95691. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee KH, Lin FC, Hsu TI, Lin JT, Guo JH,
Tsai CH, Lee YC, Lee YC, Chen CL, Hsiao M, et al: MicroRNA-296-5p
(miR-296-5p) functions as a tumor suppressor in prostate cancer by
directly targeting Pin1. Biochim Biophys Acta. 1843:2055–2066.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yan W, Chen J, Chen Z and Chen H:
Deregulated miR-296/S100A4 axis promotes tumor invasion by inducing
epithelial-mesenchymal transition in human ovarian cancer. Am J
Cancer Res. 6:260–269. 2016.PubMed/NCBI
|
|
9
|
Luo W, Lin Y, Meng S, Guo Y, Zhang J and
Zhang W: miRNA-296-3p modulates chemosensitivity of lung cancer
cells by targeting CX3CR1. Am J Transl Res. 8:1848–1856.
2016.PubMed/NCBI
|
|
10
|
Savi F, Forno I, Faversani A, Luciani A,
Caldiera S, Gatti S, Foa P, Ricca D, Bulfamante G, Vaira V, et al:
miR-296/Scribble axis is deregulated in human breast cancer and
miR-296 restoration reduces tumour growth in vivo. Clin Sci (Lond).
127:233–242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kunte DP, DelaCruz M, Wali RK, Menon A, Du
H, Stypula Y, Patel A, Backman V and Roy HK: Dysregulation of
microRNAs in colonic field carcinogenesis: Implications for
screening. PLoS One. 7:e455912012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Witherow DS, Garrison TR, Miller WE and
Lefkowitz RJ: beta-Arrestin inhibits NF-kappaB activity by means of
its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc
Natl Acad Sci USA. 101:8603–8607. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miele E, Po A, Begalli F, Antonucci L,
Mastronuzzi A, Marras CE, Carai A, Cucchi D, Abballe L, Besharat
ZM, et al: β-arrestin1-mediated acetylation of Gli1 regulates
Hedgehog/Gli signaling and modulates self-renewal of SHH
medulloblastoma cancer stem cells. BMC Cancer. 17:4882017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kraemer A, Barjaktarovic Z, Sarioglu H,
Winkler K, Eckardt-Schupp F, Tapio S, Atkinson MJ and Moertl S:
Cell survival following radiation exposure requires miR-525-3p
mediated suppression of ARRB1 and TXN1. PLoS One. 8:e774842013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M,
Zhang M, Bao G, Wang F, Zhang X, et al: A nuclear function of
beta-arrestin1 in GPCR signaling: Regulation of histone acetylation
and gene transcription. Cell. 123:833–847. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parathath SR, Mainwaring LA, Fernandez-L
A, Guldal CG, Nahlé Z and Kenney AM: β-Arrestin-1 links mitogenic
sonic hedgehog signaling to the cell cycle exit machinery in neural
precursors. Cell Cycle. 9:4013–4024. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang Y, Guo Y, Tan S, Ke B, Tao J, Liu H,
Jiang J, Chen J, Chen G and Wu B: β-Arrestin1 enhances
hepatocellular carcinogenesis through inflammation-mediated Akt
signalling. Nat Commun. 6:73692015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zecchini V, Madhu B, Russell R,
Pértega-Gomes N, Warren A, Gaude E, Borlido J, Stark R,
Ireland-Zecchini H, Rao R, et al: Nuclear ARRB1 induces
pseudohypoxia and cellular metabolism reprogramming in prostate
cancer. EMBO J. 33:1365–1382. 2014.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma H, Wang L, Zhang T, Shen H and Du J:
Loss of β-arrestin1 expression predicts unfavorable prognosis for
non-small cell lung cancer patients. Tumour Biol. 37:1341–1347.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hong L, Han Y, Zhang H, Li M, Gong T, Sun
L, Wu K, Zhao Q and Fan D: The prognostic and chemotherapeutic
value of miR-296 in esophageal squamous cell carcinoma. Ann Surg.
251:1056–1063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Q, Qian J, Wang J, Luo C, Chen J, Hu
G and Lu Y: Knockdown of RLIP76 expression by RNA interference
inhibits invasion, induces cell cycle arrest, and increases
chemosensitivity to the anticancer drug temozolomide in glioma
cells. J Neurooncol. 112:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shivapurkar N, Mikhail S, Navarro R, Bai
W, Marshall J, Hwang J, Pishvaian M, Wellstein A and He AR:
Decrease in blood miR-296 predicts chemotherapy resistance and poor
clinical outcome in patients receiving systemic chemotherapy for
metastatic colon cancer. Int J Colorectal Dis. 28:8872013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He Z, Yu L, Luo S, Li M, Li J, Li Q, Sun Y
and Wang C: miR-296 inhibits the metastasis and
epithelial-mesenchymal transition of colorectal cancer by targeting
S100A4. BMC Cancer. 17:1402017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu Q, Song X, Liu Z, Deng X, Luo R, Ge C,
Li R, Li Z, Zhao M, Chen Y, et al: miRomics and proteomics reveal a
miR-296-3p/PRKCA/FAK/Ras/c-Myc feedback loop modulated by
HDGF/DDX5/β-catenin complex in lung adenocarcinoma. Clin Cancer
Res. 23:6336–6350. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deng X, Liu Z, Liu X, Fu Q, Deng T, Lu J,
Liu Y, Liang Z, Jiang Q, Cheng C, et al: miR-296-3p negatively
regulated by nicotine stimulates cytoplasmic translocation of c-Myc
via MK2 to suppress chemotherapy resistance. Mol Ther.
26:1066–1081. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li H, Li J, Shi B and Chen F: MicroRNA-296
targets AKT2 in pancreatic cancer and functions as a potential
tumor suppressor. Mol Med Rep. 16:466–472. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma L and Pei G: Beta-arrestin signaling
and regulation of transcription. J Cell Sci. 120:213–218. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang YX, Li XF, Yuan GQ, Hu H, Song XY,
Li JY, Miao XK, Zhou TX, Yang WL, Zhang XW, et al: β-Arrestin 1 has
an essential role in neurokinin-1 receptor-mediated glioblastoma
cell proliferation and G2/M phase transition. J Biol Chem.
292:8933–8947. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guzińska-Ustymowicz K, Pryczynicz A,
Kemona A and Czyzewska J: Correlation between proliferation
markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in
colorectal cancer. Anticancer Res. 29:3049–3052. 2009.PubMed/NCBI
|
|
31
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
